Is Elanco Animal Health (ELAN) A Bargain After New Credelio Quattro Tick Data?
Elanco Animal Health (ELAN) is back in focus after new studies reported that its Credelio Quattro chewable tablets kill black-legged and lone star ticks more quickly and consistently than key competitors throughout the monthly dosing period.
See our latest analysis for Elanco Animal Health.
The Credelio Quattro data lands at a time when Elanco Animal Health’s share price is US$25.52, with a 90 day share price return of 17.06% and a 1 year total shareholder return of 77.35%, although the 5 year total shareholder return has declined 30.50%.
If you are weighing this momentum and want more ideas in pet and animal care, it can help to widen your search using our healthcare focused AI stock screener, starting with 40 healthcare AI stocks.
Elanco Animal Health’s sharp rebound, alongside improving revenue and net income figures, raises a clear question for investors: Is this mainly a reset in sentiment after weaker long term returns, or a fair reflection of today’s fundamentals and valuation?
Most Popular Narrative: 14.3% Undervalued
Elanco Animal Health’s most widely followed narrative points to a fair value of $29.79 per share compared with the current price of $25.52. This puts the recent tick-borne parasite news into a broader earnings and valuation context.
The successful launch of six potential blockbuster products and exceeding innovation revenue targets for 2024 positions Elanco for strong innovation contributions in 2025, expected to increase innovation revenue, positively influencing earnings.
Operational focus on product launches and divesting non-core businesses such as the Aqua division has enabled debt reduction and increased investment capacity, which should improve net margins and financial stability.
Want to see what sits behind that fair value for Elanco Animal Health? The narrative emphasizes earnings power, margin repair and a richer multiple that many investors may not be expecting.
Result: Fair Value of $29.79 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there is still meaningful execution risk for Elanco Animal Health if new products such as Credelio Quattro and Zenrelia see slower adoption, or if veterinary clinic uptake disappoints.
Find out about the key risks to this Elanco Animal Health narrative.
Next Steps
With sentiment on Elanco Animal Health tilting more positive, it makes sense to move quickly and test the numbers yourself before views settle. Take a closer look at the company’s potential by reviewing its 3 key rewards
Looking for more investment ideas beyond Elanco Animal Health?
If you are serious about building a stronger portfolio, do not stop with Elanco Animal Health. Use the Simply Wall Street Screener to uncover other opportunities now.
- Target potential mispricings by scanning for quality companies trading below their assessed value through the 49 high quality undervalued stocks.
- Strengthen your income stream by reviewing companies with higher yields and resilient payouts using the 8 dividend fortresses.
- Prioritise resilience by checking out companies that score well on balance sheet strength and fundamentals via the solid balance sheet and fundamentals stocks screener (48 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com